our Premium Content: News alerts, weekly reports and conference planners

GENE:

NFKBIA (NFKB Inhibitor Alpha 2)

News alerts, weekly reports and conference planners

Glycogen synthase 1 promotes breast cancer progression by promoting IκBα ubiquitination and degradation independent of its canonical enzyme function. (PubMed, Cell Commun Signal)

GYS1 stabilizes the interaction between IκBα and its E3 ubiquitin ligase BTRC, facilitating IκBα proteasomal degradation and enabling nuclear translocation of NF-κB. Our findings establish GYS1 as a novel scaffold protein and an upstream regulator of NF-κB signaling independent of its enzymatic function, nominating it as a promising therapeutic target for breast cancer particularly for TNBC subtype that lacks effective treatment.

4 days ago

Journal

NFKBIA (NFKB Inhibitor Alpha 2)

12d

AQP4-IgG-Induced Astrocyte-Derived Small Extracellular Vesicles Carrying Mitochondrial DNA Regulate the TLR9/MyD88/NF-κB Pathway to Drive Microglial Activation and Neuromyelitis Optica. (PubMed, Neurochem Res)

In vivo, AQP4-IgG-induced EVs-mtDNA exacerbated microglial activation and NMO through the TLR9/MyD88/NF-κB pathway. AQP4-IgG-induced EVs carried mtDNA to upregulate TLR9, further activating the MyD88/NF-κB pathway, thereby promoting microglial activation and transition toward pro-inflammatory gene-high-expressing cells to drive NMO progression.

12 days ago

Journal

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFA (Tumor Necrosis Factor-Alpha) • MRC1 (Mannose Receptor C-Type 1) • NFKBIA (NFKB Inhibitor Alpha 2) • CD86 (CD86 Molecule)

14d

PLS3-AS1 promotes colorectal cancer progression and radioresistance by sustaining NF-κB signaling. (PubMed, Biochem Biophys Res Commun)

Inhibition of NF-κB with BAY 11-7082 suppressed PLS3-AS1 expression and reversed its pro-tumorigenic effects. These findings identify PLS3-AS1 as a critical mediator of NF-κB-driven radioresistance in CRC and a potential therapeutic target to improve radiotherapy efficacy.

14 days ago

Journal

NFKBIA (NFKB Inhibitor Alpha 2)

Bay11-7082

14d

Renqingchangjue ameliorates MNNG-induced chronic atrophic gastritis by inhibiting the TNF/NF-κB/Caspase-3 axis. (PubMed, Phytomedicine)

Together, these multi-level data indicate that RQCJ exerts clinically relevant protection against CAG via multi-component suppression of TNF-NF-κB/Caspase-3 axis, broad rebalancing of pro-/anti-inflammatory cytokines, and restoration of gastric function.

14 days ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CCL2 (Chemokine (C-C motif) ligand 2) • MMP9 (Matrix metallopeptidase 9) • GAST (Gastrin 2) • IL1B (Interleukin 1, beta) • NFKBIA (NFKB Inhibitor Alpha 2) • ANXA5 (Annexin A5) • CXCL1 (Chemokine (C-X-C motif) ligand 1)

21d

Carnosol enhances radiosensitivity in NSCLC cells by targeting the miR-17-5p/TOLLIP/NF-κB Axis. (PubMed, Toxicol Res (Camb))

miR-17-5p mimics partially reversed these effects. Carnosol may exert its radiosensitizing effect in NSCLC by targeting the miR-17-5p/TOLLIP/NF-κB axis and disrupting DNA repair, highlighting its therapeutic potential in overcoming radioresistance.

21 days ago

Journal

RAD51 (RAD51 Homolog A) • TLR4 (Toll Like Receptor 4) • MIR17 (MicroRNA 17) • NFKBIA (NFKB Inhibitor Alpha 2)

21d

LAR1 promotes breast carcinogenesis by activating NF-κB signaling pathway through binding and enhancing APOC1 expression. (PubMed, iScience)

LAR1 bound to the APOC1 3'-UTR to stabilize its mRNA, and APOC1 overexpression counteracted the effects of LAR1 knockdown. In conclusion, our study defines the LAR1-APOC1-NF-κB axis as a crucial driver of BC progression, offering a promising therapeutic strategy for BC treatment.

21 days ago

Journal

NFKBIA (NFKB Inhibitor Alpha 2)

24d

Enhanced ADP-heptose-dependent NF-κB activation by Helicobacter pylori CagA through cortactin-Src-dependent tyrosine phosphorylation of IKKβ. (PubMed, Microlife)

These data demonstrate that ADPH-dependent NF-κB activation and IL-8 secretion are enhanced by CagA. Together, we present here a novel CagA>cortactin>FAK>Src>IKKβ signaling cascade, contributing to proinflammatory responses by H. pylori.

24 days ago

Journal

CXCL8 (Chemokine (C-X-C motif) ligand 8) • NFKBIA (NFKB Inhibitor Alpha 2) • CTTN (Cortactin)

25d

FBXL8 Stabilizes IκBα and Negatively Regulated NF-κB Activation to Suppress Pancreatic Cancer Progression. (PubMed, Int J Biol Sci)

In conclusion, this study reveals that FBXL8 suppresses PC progression by stabilizing IκBα through non-degradative ubiquitination, and its downregulation via the NF-κB-YY1 axis promotes oncogenic progression. The FBXL8-IκBα-NF-κB pathway represents a promising novel therapeutic target for PC.

25 days ago

Journal

NFKBIA (NFKB Inhibitor Alpha 2) • YY1 (YY1 Transcription Factor)

25d

Prenatal-lactational alcohol exposure induces sex-specific CX3CL1/CX3CR1 dysregulation linked to neuroendocrine imbalance and cardiovascular risk. (PubMed, Brain Behav Immun)

PLAE is associated with sex-specific dysregulation of the CX3CL1/CX3CR1 axis and convergent neuroimmune-vascular signatures indicative of subclinical endothelial dysfunction. These associative findings support the hypothesis that fractalkine-pathway modulation may mitigate long-term neurobehavioral and cardiovascular vulnerability after PLAE, warranting causal testing.

25 days ago

Journal

TNFRSF1A (TNF Receptor Superfamily Member 1A) • IL18 (Interleukin 18) • TLR4 (Toll Like Receptor 4) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • IL13 (Interleukin 13) • IL5 (Interleukin 5) • NFKBIA (NFKB Inhibitor Alpha 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • CXCL16 (C-X-C Motif Chemokine Ligand 16)

27d

IRAK4 Regulates NF-κB signaling to suppress CD8 + T cell activity and promote immune evasion in glioblastoma development. (PubMed, Cancer Immunol Immunother)

These findings highlight IRAK4 as a key regulator of NF-κB-mediated immune evasion in glioblastoma, suggesting its potential as a therapeutic target to enhance CD8+ T cell-based immunotherapy. This study provides novel insights into glioblastoma's immune regulatory mechanisms and supports the development of targeted immunotherapies.

27 days ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • NFKBIA (NFKB Inhibitor Alpha 2) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)

28d

Utilization of machine learning algorithms for the identification of the RLN associated prognostic model and feature biomarkers of RLN-related subtypes in breast cancer. (PubMed, Transl Oncol)

The identification of TRAPM and the RC3 subtype enhances our understanding of BC heterogeneity and highlights potential therapeutic targets. This study provides a foundation for personalized treatment strategies by clarifying the biological significance and clinical relevance of the RC3 subtype.

28 days ago

Journal • BRCA Biomarker • IO biomarker

BRCA (Breast cancer early onset) • MMP9 (Matrix metallopeptidase 9) • ADGRG6 (Adhesion G Protein-Coupled Receptor G6) • MMP1 (Matrix metallopeptidase 1) • NFKBIA (NFKB Inhibitor Alpha 2) • NOS2 (Nitric Oxide Synthase 2) • SMYD2 (SET And MYND Domain Containing 2)

CXCL14 Promotes Ovarian Cancer Progression and Autophagy Through the IKBKE/NF-κB Pathway. (PubMed, J Gene Med)

In vivo, CXCL14 overexpression markedly enhances ovarian tumor growth, accompanied by increased levels of IKBKE and phosphorylated p65. These findings elucidate a novel regulatory axis, CXCL14/IKBKE/NF-κB, in ovarian cancer progression, highlighting CXCL14 as a potential therapeutic target for ovarian cancer treatment.

1 month ago

Journal

IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • NFKBIA (NFKB Inhibitor Alpha 2) • CXCL14 (C-X-C Motif Chemokine Ligand 14)